Jönsson B, Carlsson P
Department of Health and Society, Linköping University, Sweden.
Soc Sci Med. 1991;33(3):275-82. doi: 10.1016/0277-9536(91)90361-f.
The economic impact of the drug cimetidine on the direct and indirect costs of ulcer disease was studied. Cimetidine appeared on the Swedish market in 1978. Unlike other innovations, whose spread is normally slow during the initial period, cimetidine was introduced very swiftly and its use quickly expanded. It was expected that it would reduce the number of elective ulcer operations, with resulting savings in medical care resources exceeding the cost of the new drug. The use of cimetidine was also expected to reduce the indirect costs related to short- and long-term illness. The aims of the study were: (1) to describe and calculate the economic impact of the introduction of cimetidine; (2) to compare the retrospective calculations with the prospective calculations; and (3) to investigate how routinely collected data could serve as a complement to studies of efficacy, effectiveness, and cost-effectiveness. Retrospective calculation of the economic effects shows that cimetidine has in fact increased the direct costs of medical care. On the other hand, the drop in indirect costs due to reduced long-term absence (disability) from work, and reduced short-term absence from work, exceeded the increase in the cost of medical care. Thus, the total economic cost of peptic ulcer disease was reduced.
研究了西咪替丁药物对溃疡病直接和间接成本的经济影响。西咪替丁于1978年出现在瑞典市场。与其他创新不同，其传播在初始阶段通常较为缓慢，西咪替丁被迅速引入且其使用迅速扩大。预计它将减少择期溃疡手术的数量，从而节省的医疗资源超过新药成本。西咪替丁的使用还预计会减少与短期和长期疾病相关的间接成本。该研究的目的是：（1）描述和计算引入西咪替丁的经济影响；（2）将回顾性计算与前瞻性计算进行比较；（3）研究常规收集的数据如何能作为疗效、有效性和成本效益研究的补充。对经济影响的回顾性计算表明，西咪替丁实际上增加了医疗护理的直接成本。另一方面，由于长期缺勤（残疾）减少以及短期缺勤减少导致的间接成本下降超过了医疗护理成本的增加。因此，消化性溃疡病的总经济成本降低了。
